Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
BACKGROUND: Drug-resistance mutations (DRAM) are frequently selected in patients with virological failure defined as viral load (pVL) above 500 copies/ml (c/mL), but few resistance data are available at low-level viremia (LLV).Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving an